Semaglutide · Ozempic, Rybelsus

What is Semaglutide?

Semaglutide is a GLP-1 receptor agonist peptide with 94% sequence homology to human GLP-1. It binds and activates the GLP-1 receptor, stimulating glucose-dependent insulin secretion and inhibiting glucagon secretion to lower blood glucose.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Ozempic, Rybelsus, Wegovy, NN-9535, NNC 0113-0217

Drug type

Peptide

Targets

GLP-1 receptor (GLP1R)

Mechanism

Agonist of GLP-1 receptor (GLP1R)

Pathways

insulin secretion, glucagon inhibition, gastric emptying

Therapy area

Metabolic

Developer

Novo

In trials of

LEXX, VERU

FDA status

Approved as Ozempic, Rybelsus, Wegovy (December 5, 2017), NDA209637 · FDA label

UNII

53AXN4NNHX

✅ FDA-approved uses

• Type 2 diabetes mellitus (Ozempic)
• Major adverse cardiovascular events in type 2 diabetes with established cardiovascular disease (Ozempic)
• Sustained eGFR decline and end-stage kidney disease in type 2 diabetes with chronic kidney disease (Ozempic)
• Obesity (Wegovy)
• Overweight with weight-related comorbid condition (Wegovy)
• Major adverse cardiovascular events in established cardiovascular disease with obesity or overweight (Wegovy)

From the indications section of the FDA label (version of Jul 30, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HOMA-IRMobility DisabilityObesity & OverweightType2diabetes

Other drugs acting on GLP1R

Sources

• FDA label (DailyMed)
• FDA label Ozempic (2026-07-30), indications
• FDA label Wegovy (2024-04-23), indications
• ClinicalTrials.gov NCT06648031
• ClinicalTrials.gov NCT07446998

Updated Oct 3, 2026.